Apollo Endosurgery, Inc. (NASDAQ:APEN) major shareholder Stonepine Capital, L.P. bought 45,434 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The stock was purchased at an average price of $4.50 per share, with a total value of $204,453.00. Following the transaction, the insider now directly owns 2,410,141 shares in the company, valued at $10,845,634.50. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Stonepine Capital, L.P. also recently made the following trade(s):
- On Friday, December 22nd, Stonepine Capital, L.P. bought 185,157 shares of Apollo Endosurgery stock. The stock was purchased at an average price of $4.85 per share, with a total value of $898,011.45.
Shares of Apollo Endosurgery, Inc. (NASDAQ:APEN) opened at $5.10 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.54 and a quick ratio of 2.00. Apollo Endosurgery, Inc. has a 12-month low of $3.55 and a 12-month high of $21.88. The firm has a market capitalization of $89.59, a P/E ratio of -0.23 and a beta of 0.46.
Several analysts have weighed in on APEN shares. Northland Securities started coverage on Apollo Endosurgery in a research report on Tuesday, September 26th. They issued an “outperform” rating and a $12.00 price objective for the company. Zacks Investment Research upgraded Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $9.44.
About Apollo Endosurgery
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.